Rocket Pharmaceuticals Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 202

Employees

  • Stock Symbol
  • RCKT

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.97
  • (As of Friday Closing)

Rocket Pharmaceuticals General Information

Description

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Contact Information

Formerly Known As
Inotek Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 9 Cedarbrook Drive
  • Cranbury, NJ 08512
  • United States
+1 (646)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 9 Cedarbrook Drive
  • Cranbury, NJ 08512
  • United States
+1 (646)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rocket Pharmaceuticals Stock Performance

As of 20-Nov-2026, Rocket Pharmaceuticals’s stock price is $1.97. Its current market cap is $218M with 112M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.97 $2.11 $1.94 - $5.45 $218M 112M 1.89M -$0.15

Rocket Pharmaceuticals Financials Summary

As of 30-Sep-2026, Rocket Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 29,758 182,147 1,126,637 2,290,074
Revenue 0 0 0 0
EBITDA (3,676) (220,722) (263,830) (252,561)
Net Income (16,152) (223,123) (258,746) (245,595)
Total Assets 419,504 330,449 527,700 566,341
Total Debt 55,042 24,877 25,498 25,042
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rocket Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rocket Pharmaceuticals‘s full profile, request access.

Request a free trial

Rocket Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies
Biotechnology
Cranbury, NJ
202 As of 2025

Boston, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rocket Pharmaceuticals Competitors (81)

One of Rocket Pharmaceuticals’s 81 competitors is Rhythm Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA
Vaxart Formerly VC-backed South San Francisco, CA
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Alector Formerly VC-backed South San Francisco, CA
Avalo Therapeutics Formerly VC-backed Wayne, PA
You’re viewing 5 of 81 competitors. Get the full list »

Rocket Pharmaceuticals Patents

Rocket Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020237219-A1 Gene therapy vectors for infantile malignant osteopetrosis Inactive 23-May-2019
WO-2020167996-A1 Gene therapy vectors for treatment of danon disease Inactive 12-Feb-2019
US-20210198695-A1 Production methods for viral vectors Inactive 16-Aug-2018
WO-2020037249-A1 Production methods for viral vectors Inactive 16-Aug-2018
WO-2020028430-A1 Methods for gene modification of hematopoietic cells Inactive 30-Jul-2018 A61K35/28
To view Rocket Pharmaceuticals’s complete patent history, request access »

Rocket Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rocket Pharmaceuticals Acquisitions (2)

Rocket Pharmaceuticals’s most recent deal was a Merger/Acquisition with Renovacor for . The deal was made on 01-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Renovacor 01-Dec-2022 Merger/Acquisition Drug Discovery
Inotek Pharmaceuticals 04-Jan-2018 Merger/Acquisition Drug Discovery
To view Rocket Pharmaceuticals’s complete acquisitions history, request access »

Rocket Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Rocket Pharmaceuticals’s complete esg history, request access »

Rocket Pharmaceuticals FAQs

  • When was Rocket Pharmaceuticals founded?

    Rocket Pharmaceuticals was founded in 1999.

  • Where is Rocket Pharmaceuticals headquartered?

    Rocket Pharmaceuticals is headquartered in Cranbury, NJ.

  • What is the size of Rocket Pharmaceuticals?

    Rocket Pharmaceuticals has 202 total employees.

  • What industry is Rocket Pharmaceuticals in?

    Rocket Pharmaceuticals’s primary industry is Biotechnology.

  • Is Rocket Pharmaceuticals a private or public company?

    Rocket Pharmaceuticals is a Public company.

  • What is Rocket Pharmaceuticals’s stock symbol?

    The ticker symbol for Rocket Pharmaceuticals is RCKT.

  • What is the current stock price of Rocket Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Rocket Pharmaceuticals is $1.97.

  • What is the current market cap of Rocket Pharmaceuticals?

    The current market capitalization of Rocket Pharmaceuticals is $218M.

  • Who are Rocket Pharmaceuticals’s competitors?

    Rhythm Pharmaceuticals, Vaxart, Denali Therapeutics, Alector, and Avalo Therapeutics are some of the 81 competitors of Rocket Pharmaceuticals.

  • What is Rocket Pharmaceuticals’s annual earnings per share (EPS)?

    Rocket Pharmaceuticals’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process